2020 January 8, 2020
Eli Lilly Pulls Away from Bispecific Antibodies
1 min read
Eli Lilly announced that it is pulling the plug on LY3415244, the company’s only bispecific antibody currently in pipeline (see attached article). So which modalities is Eli Lilly investing in? Kognitic has a great breadth of data for each company’s assets, including trial phase, modality, target, indication, and more! This data is then presented through crisp visuals, such as the landscape view below, which allow users to easily make sense of an extensive set of data.